Skip to content

Study · Not a test of the peptide alone · 2026

13 results

Timeliness of antiresorptive consolidation after anabolic therapy for primary fracture prevention: A US cohort study.

Badour S, McCoy RG, Takagi M, Everhart AO, Parimi J, Herrin J, Karaca-Mandic P, Wermers RA, Rosen CJ, Brito JP

The Journal of clinical endocrinology and metabolism1 Jul 2026Cited by 1 (Europe PMC)

PMID41778369 (opens in a new tab)PMCIDPMC13220338 (opens in a new tab)DOI10.1210/clinem/dgag092 (opens in a new tab)PepBankPUB-41778369
Source linkPubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone13

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    Among pooled osteoanabolic users including abaloparatide, 25% received timely consolidation.

    In plain wordsAmong pooled bone-building drug users including abaloparatide, 25% received timely follow-on treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableTimely consolidation
    Study

    n = 15,389

    Analysis
    Primary
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Timely consolidation
    25%
    Pooled osteoanabolic users

    Source sentences

    Summary
    Overall, 25% had timely consolidation, 24% delayed consolidation, 12% restarted osteoanabolics, and 40% had no consolidation; only 12% completed therapy with timely consolidation.
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 02HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    Among pooled osteoanabolic users including abaloparatide, 24% received delayed consolidation.

    In plain wordsAmong pooled bone-building drug users including abaloparatide, 24% received delayed follow-on treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableDelayed consolidation
    Study

    n = 15,389

    Analysis
    Secondary
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Delayed consolidation
    24%
    Pooled osteoanabolic users

    Source sentences

    Summary
    Overall, 25% had timely consolidation, 24% delayed consolidation, 12% restarted osteoanabolics, and 40% had no consolidation; only 12% completed therapy with timely consolidation.
    4 context sentences
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data.
    Summary · context
    Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included.
    Summary · context
    The primary outcome was timely consolidation, defined as initiation of an antiresorptive medication within 3 months after osteoanabolic therapy.
    Summary · context
    Secondary outcomes included delayed consolidation (initiation >3 months after completion), osteoanabolic restart following a treatment gap, and no consolidation therapy.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  3. 03HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    Among pooled osteoanabolic users including abaloparatide, 12% restarted osteoanabolics.

    In plain wordsAmong pooled bone-building drug users including abaloparatide, 12% restarted treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableOsteoanabolic restart
    Study

    n = 15,389

    Analysis
    Secondary
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Osteoanabolic restart
    12%
    Pooled osteoanabolic users

    Source sentences

    Summary
    Overall, 25% had timely consolidation, 24% delayed consolidation, 12% restarted osteoanabolics, and 40% had no consolidation; only 12% completed therapy with timely consolidation.
    4 context sentences
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data.
    Summary · context
    Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included.
    Summary · context
    The primary outcome was timely consolidation, defined as initiation of an antiresorptive medication within 3 months after osteoanabolic therapy.
    Summary · context
    Secondary outcomes included delayed consolidation (initiation >3 months after completion), osteoanabolic restart following a treatment gap, and no consolidation therapy.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  4. 04HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    Among pooled osteoanabolic users including abaloparatide, 40% received no consolidation.

    In plain wordsAmong pooled bone-building drug users including abaloparatide, 40% received no follow-on treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableNo consolidation
    Study

    n = 15,389

    Analysis
    Secondary
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    No consolidation
    40%
    Pooled osteoanabolic users

    Source sentences

    Summary
    Overall, 25% had timely consolidation, 24% delayed consolidation, 12% restarted osteoanabolics, and 40% had no consolidation; only 12% completed therapy with timely consolidation.
    4 context sentences
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data.
    Summary · context
    Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included.
    Summary · context
    The primary outcome was timely consolidation, defined as initiation of an antiresorptive medication within 3 months after osteoanabolic therapy.
    Summary · context
    Secondary outcomes included delayed consolidation (initiation >3 months after completion), osteoanabolic restart following a treatment gap, and no consolidation therapy.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  5. 05HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    Among pooled osteoanabolic users including abaloparatide, 30% completed therapy.

    In plain wordsAmong users of pooled bone-building drugs including abaloparatide, 30% completed treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableTherapy completion
    Study

    n = 15,389

    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Therapy completion
    30%
    Pooled osteoanabolic users

    Source sentences

    Summary
    Among 15 389 patients (mean age 70.6 years; 89% women; 85% White), 30% completed osteoanabolic therapy (median, 12.9 months for romosozumab; 23.4 months for teriparatide/abaloparatide).
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  6. 06HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    Among pooled osteoanabolic users including abaloparatide, 12% completed therapy with timely consolidation.

    In plain wordsAmong pooled bone-building drug users including abaloparatide, 12% completed treatment and received timely follow-on treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableCompletion with timely consolidation
    Study

    n = 15,389

    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Completion with timely consolidation
    12%
    Pooled osteoanabolic users

    Source sentences

    Summary
    Overall, 25% had timely consolidation, 24% delayed consolidation, 12% restarted osteoanabolics, and 40% had no consolidation; only 12% completed therapy with timely consolidation.
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  7. 07HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In pooled osteoanabolic users including abaloparatide, endocrinology care was linked to more timely consolidation than primary care.

    In plain wordsAmong pooled drug users including abaloparatide, endocrinology care was linked to more timely follow-on treatment than primary care.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseConsolidation and endocrinology care
    Study

    n = 15,389

    Comparator
    Primary care
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Odds ratio
    1.31 ratio
    Endocrinology versus primary care
    Lower confidence bound
    1.17 ratio
    95% CI
    Upper confidence bound
    1.48 ratio
    95% CI

    Source sentences

    Summary
    Timely consolidation was more likely with endocrinology (OR 1.31; 95% CI, 1.17-1.48) or rheumatology (OR 1.45; 1.30-1.62) vs primary care,
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  8. 08HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In pooled osteoanabolic users including abaloparatide, rheumatology care was linked to more timely consolidation than primary care.

    In plain wordsAmong pooled drug users including abaloparatide, rheumatology care was linked to more timely follow-on treatment than primary care.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseConsolidation and rheumatology care
    Study

    n = 15,389

    Comparator
    Primary care
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Odds ratio
    1.45 ratio
    Rheumatology versus primary care
    Lower confidence bound
    1.3 ratio
    95% CI
    Upper confidence bound
    1.62 ratio
    95% CI

    Source sentences

    Summary
    Timely consolidation was more likely with endocrinology (OR 1.31; 95% CI, 1.17-1.48) or rheumatology (OR 1.45; 1.30-1.62) vs primary care,
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  9. 09HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In pooled osteoanabolic users including abaloparatide, age 50-64 was linked to less timely consolidation than age 65-74.

    In plain wordsAmong pooled drug users including abaloparatide, people aged 50-64 had less timely follow-on treatment than those aged 65-74.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseConsolidation and age
    Study

    n = 15,389

    Comparator
    Age 65-74
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Odds ratio
    0.67 ratio
    Age 50-64 versus 65-74
    Lower confidence bound
    0.58 ratio
    95% CI
    Upper confidence bound
    0.77 ratio
    95% CI

    Source sentences

    Summary
    and less likely among patients aged 50-64 years (OR 0.67; 0.58-0.77) vs 65-74,
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  10. 10HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In pooled osteoanabolic users including abaloparatide, Medicare Advantage was linked to less timely consolidation than traditional Medicare.

    In plain wordsAmong pooled drug users including abaloparatide, Medicare Advantage was linked to less timely follow-on treatment than traditional Medicare.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseConsolidation and insurance
    Study

    n = 15,389

    Comparator
    Traditional Medicare
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Odds ratio
    0.85 ratio
    Medicare Advantage versus traditional Medicare
    Lower confidence bound
    0.74 ratio
    95% CI
    Upper confidence bound
    0.98 ratio
    95% CI

    Source sentences

    Summary
    those enrolled in Medicare Advantage (OR 0.85; 0.74-0.98) vs traditional Medicare,
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  11. 11HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In pooled osteoanabolic users including abaloparatide, recent hospitalization was linked to less timely consolidation.

    In plain wordsAmong pooled drug users including abaloparatide, recent hospitalization was linked to less timely follow-on treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseTimely consolidation by recent hospitalization
    Study

    n = 15,389

    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Odds ratio
    0.88 ratio
    Recent hospitalization
    Lower confidence bound
    0.8 ratio
    95% CI
    Upper confidence bound
    0.97 ratio
    95% CI

    Source sentences

    Summary
    or those recently hospitalized (OR 0.88; 0.80-0.97).
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  12. 12HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In pooled osteoanabolic users including abaloparatide, timely consolidation odds increased for 2021 versus 2011 starts.

    In plain wordsAmong pooled drug users including abaloparatide, timely follow-on treatment was more likely for 2021 than 2011 starts.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseConsolidation over calendar time
    Study

    n = 15,389

    Comparator
    2011 starts
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Odds ratio
    4.27 ratio
    2021 versus 2011 starts
    Lower confidence bound
    3.63 ratio
    95% CI
    Upper confidence bound
    5.05 ratio
    95% CI

    Source sentences

    Summary
    Odds increased over time (OR 4.27; 3.63-5.05 for 2021 vs 2011 starts).
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  13. 13HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    The pooled teriparatide/abaloparatide group had a median treatment duration of 23.4 months.

    In plain wordsThe combined teriparatide and abaloparatide group had a median treatment duration of 23.4 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableTreatment duration
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Median treatment duration
    23.4 months
    Pooled teriparatide/abaloparatide

    Source sentences

    Summary
    Among 15 389 patients (mean age 70.6 years; 89% women; 85% White), 30% completed osteoanabolic therapy (median, 12.9 months for romosozumab; 23.4 months for teriparatide/abaloparatide).
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initi…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.